FDA Advisory Committee to Meet on Next Season's Flu Vaccine
Vaccines and Related Biological Products Advisory Committee will meet March 6-7 in Silver Spring, Md., to discuss and make recommendations on the selection of strains to be included in the influenza virus vaccines for the 2019-2020 flu season.
The Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee will meet March 6-7 in Silver Spring, Md., to discuss and make recommendations on the selection of strains to be included in the influenza virus vaccines for the 2019-2020 flu season. It is an open meeting, although part of the meeting will be closed to the public, according to FDA's notice.
The meeting will be held March 6 from 8 a.m. to 4:30 p.m. and March 7 from 8:30 a.m. to 4:45 p.m. at the FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, Room 1503.
The flu vaccines discussion will be in open session March 6. Also on March 6, the committee will meet in open session to hear an overview of the research programs in the Laboratory of Immunoregulation and the Laboratory of Retroviruses, Division of Viral Products, Office of Vaccines Research and Review. On March 7, the committee will meet in open session to discuss and make recommendations on the safety and effectiveness of Dengue Tetravalent Vaccine (Live, Attenuated) (DENGVAXIA) manufactured by Sanofi Pasteur.